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Abstract
Background: PLA2G6-associated neurodegeneration (PLAN) is a recessive neurodegenerative disorder characterized by three distinct phenotypes: infantile
neuroaxonal dystrophy (INAD), atypical neuroaxonal dystrophy (atypical NAD), and PLA2G6-related dystonia–parkinsonism.
Methods: A consanguineous index case from Turkey was diagnosed with early-onset Parkinsonism at the Istanbul Faculty of Medicine. She and her unaffected
brother were subjected to whole-genome sequencing.
Results: In this report, we describe a 33-year-old index case with parental consanguinity and early-onset Parkinsonism. Whole-genome sequencing of this
individual revealed that a homozygous p.R747W mutation in PLA2G6 segregates with the disease in this family
Discussion: This result supports the importance of prioritizing this gene in mutational analysis of autosomal recessive Parkinsonism, and confirms the clinical
heterogeneity of PLAN.
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Introduction
Mutations in phospholipase A2, group VI (PLA2G6) were initially
discovered in a set of families with infantile neuroaxonal dystrophy (INAD),1
and also in a large consanguineous Pakistani family with neurodegeneration
with brain iron accumulation (NBIA) who did not have mutations in
PANK2.2 In 2009, Paisa´n-Ruiz et al.3 using magnetic resonance imaging
(MRI) identified mutations in PLA2G6 in two unrelated families with
adult-onset levodopa-responsive dystonia–parkinsonism with generalized
cerebral atrophy but no brain iron accumulation. After this discovery, muta-
tions in this gene have been associated with a broad spectrum of phenotypes,
ranging from generalized dystonia to pure recessive Parkinsonism.4–6 Because
of this heterogeneity, the term PLA2G6-associated neurodegeneration
(PLAN) has been proposed for all phenotypes associated with mutations in
this gene. The nature of this mutational pleiotropy is largely unknown.
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In this article we describe a 33-year-old Turkish patient with early-




This study was approved by the Istanbul Faculty of Medicine Ethics
Committee. The family consisted of four members, including two
offspring of whom one is affected. Blood was taken from all available
family members after obtaining informed consent. All subjects
underwent detailed clinical examination including the Unified
Parkinson’s Disease Rating Scale, Geriatric Depression Scale, and
Mini Mental State Examination.
Exclusion of PARK2 mutations
To rule out the possibility that mutations in PARK2 are the cause of
disease in this family, the complete gene coding sequence and exon–
intron boundaries in the index case were examined by Sanger sequ-
encing (primer sequences available on request). In addition, multiplex
ligation-dependent probe amplification (MLPA) with the SALSA MLPA
P051 Parkinson mix 1 probemix (MRC-Holland, www.mlpa.nl) was
used to exclude exonic rearrangements in this gene. This experiment
was performed according to the manufacturer’s protocol.
Whole-genome sequencing
The index case and her unaffected brother were subjected to whole-
genome sequencing (WGS) at Macrogen (http://www.macrogen.
com/). In brief, samples were prepared according to the Illumina
TruSeq Nano DNA library preparation guide and libraries were
sequenced using Illumina HiSeqX sequencer (www.illumina.com).
Bioinformatic analysis
Sequence reads were aligned to the reference genome (hg19) using
Isaac Genome Alignment software (https://github.com/sequencing/
isaac_aligner). Sorting, indexing, and polymerase chain reaction dupli-
cate marking was also performed with this software. Variant calling
and indel recalibration were performed with Isaac Variant Caller
v.1.0.7 (https://github.com/sequencing/isaac_variant_caller). A sin-
gle Variant Call format (VCF) file with variants identified by the
Whole Genome Study was then generated for a total of two individuals
from this family. KGGSeq (http://grass.cgs.hku.hk/limx/kggseq/)
was used to apply quality control (QC) filters on individual genotypes
and genomic variants. In brief, genotypes with a Phred quality score
below 10, a read depth under 5, the second smallest normalized Phred-
scaled genotype likelihood below 20, those with the fraction of reads
carrying>5% of the alternative allele at a reference allele homozygous
genotype, the fraction of reads carrying #25% of alternative allele at a
heterozygous genotype, or the fraction of the reads carrying #50% of
the alternative allele at an alternative-allele homozygous genotype
were set to missing (./.). Variants with the ‘‘FILTER’’ field not
matching the label ‘‘PASS,’’ a minimum overall sequencing Phred
quality score below 50, an overall mapping quality Phred score below
20, an overall strand bias Phred-scaled p-value (using Fisher’s exact
test) above 60, and those with a disease allele frequency above 1% in
the 1000 Genomes database (www.1000genomes.org), dbSNP138,
dbSNP141, the Exome Variant Server (http://evs.gs.washington.edu/
EVS/), or ExAC http://exac.broadinstitute.org/), were removed from
further analysis with KGGSeq. After this extensive QC, we were left
with a total of 4,228,886 variants. Gene-based and impact score
annotations were assigned to these variants with KGGSeq, using
RefSeq (hg19) and dbNSFP (https://sites.google.com/site/jpopgen/
dbNSFP) respectively. Intronic and synonymous variants were
consequently removed from further analysis, leaving us with a total
of 16,645 variants in the index case and her unaffected brother.
Runs of homozygosity (ROH) were identified using PLINK 1.9
(https://www.cog-genomics.org/plink2). A window of 50 single nucleotide
polymorphisms (SNPs) was defined as homozygous if it contained, at most,
one heterozygous genotype and five missing genotypes. Such windows
were moved across the genome, and an SNP was eligible for inclusion in
an ROH if the hit rate of all scanning windows containing the SNP was at
least 0.05. These are the values suggested in PLINK 1.9, designed to
minimize the probability of a window being called homozygous by chance,
while ensuring that SNPs on the edge of a true ROH will be assigned to
that ROH. Each ROH had to contain on average at least one SNP per
50 kb. The minimum length of the ROH was set at 1 Mb.
In silico analysis
Multiple sequence alignment of PLA2G6, LRRK2, and DCTN1 was
performed using Clustal omega (http://www.ebi.ac.uk/Tools/msa/
clustalo/). RaptorX (http://raptorx.uchicago.edu/) was used to predict
the three-dimensional conformation of wild type and mutated LRRK2
and DCTN1 proteins.
Results
The index case is a 33-year-old female patient with parental
consanguinity (Figure 1A) who presented with left-sided foot shuffling
and reduced arm swinging at the age of 27 years. When diagnosed with
Parkinson disease (PD), the patient was started on levodopa treatment
(levodopa/carbidopa/entacapone 100 mg/25 mg/200 mg, five times a
day), but this was changed to dopamine agonists (ropinirole 8 mg/day and
cabergoline 4 mg/day) after the appearance of irritability and restlessness.
After 2 years the patient developed severe generalized bradykinesia,
experienced difficulty walking with frequent falls, and had a bilateral hand
tremor. After increasing the doses of the anti-parkinsonian therapy
(levodopa/benserazide 750 mg/187.5 mg and amantadine 400 mg per
day), the patient developed impulse control disorder including ablutoma-
nia, pathological spending, testiness, and hypersexuality. These symptoms
improved after medication and the introduction of neuroleptics (quetiapine
25 mg/day). However, the motor symptoms worsened again, and
oromandibular dyskinesia appeared. At the time of admission in our
clinic, the patient presented with generalized severe bradykinesia,
hypomimia, hypophonia, and mild dysarthria, and was not able to stand
up or walk on her own. Intermittent micturition disturbances, postural
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Figure 1. Pedigree structure and brain imaging of the index case; and electropherogram of PLA2G6 p.R747W mutation in the index case and
her unaffected brother. (A) Pedigree of the index case (individual with blue fill) with PLA2G6 p.R747W mutation. Samples with a dot were subjected to whole-genome
sequencing. Mutant alleles are shown with a ‘‘+’’ symbol, and wild-type alleles are indicated with ‘‘2.’’ (B–E). T1 images of brain magnetic resonance imaging of the index
case, performed at the age of 30, showing no atrophy of the brainstem and cerebellum (B), marked atrophy in the right side of the frontal and temporal cortical areas (C),
asymmetrical atrophy of the right perisylvian region (D), and no atrophy of the medial, lateral, and anterior temporal areas, occipital lobes or cerebellum (E). (F) Positron
emission tomography showing significant hypometabolism in the right parietal and right temporal areas. (G) Electropherogram of PLA2G6 p.R747W mutation in the index
case (homozygous; left panel) and her unaffected brother (heterozygous; right panel). The position of this mutation is marked with a black arrow.
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instability, and tremor were noted. Deep tendon reflexes and eye
movements were normal. At the age of 30, brain MRI without contrast
enhancement, including T1, T2, fluid-attenuated inverse recovery
(FLAIR), and T2* images, revealed atrophy of the frontal and temporal
cortices, predominantly in the right side (Figure 1B–E). There was no
evidence of pathological iron accumulation in T2* images. A positron
emission tomography (PET) scan showed significant hypometabolism in
the right parietal and temporal areas (Figure 1F). The research for
metabolic diseases and neuroacanthocytosis was normal, as were
electroencephalogram (EEG) and electromyography (EMG) examinations.
Transthoracic echocardiography revealed mild mitral valve degeneration.
Neuropsychological evaluations showed impairments in language, mem-
ory, and visuospatial domains. After the establishment of a subcutaneous
apomorphine pump (5 mg/hour), the patient was able to get up and walk
on her own again. At the age of 31 the patient suffered from an epileptic
seizure after bupropion therapy (150 mg/day) for depression was
introduced. This was followed by intermittent visual hallucinations.
A new cranial MRI did not show any changes (data not shown). A video
related to this patient is provided (Video 1). The parents of the patient are
first cousins (Figure 1A) and originate from Eskisehir, a city in
northwestern Turkey. They, and the 31-year-old brother of the index
case, are healthy without any signs of neurological disease.
After excluding point mutations and exonic rearrangements in
PARK2 as the cause of disease in this family, the index case and her
unaffected brother were subjected to WGS followed by a screen of
ROH and mutation identification. A homozygous c.2239CRT
transition in a 1.04-MB ROH exclusive to the index case
(Supplementary Table S2) was identified as a result of this analysis.
This variant is located in exon 16 of PLA2G6. After Sanger sequencing,
all available family members with disease could be identified
(Figure 1G). This mutation results in a p.R747W substitution in a
highly conserved region of the encoded protein (Supplementary Figure
S1). It is not present in the 1000 Genomes database (http://www.
1000genomes.org/), the Exome Variant Server (http://evs.gs.
washington.edu/EVS/), the Turkish Genome Project (http://
turkiyegenomprojesi.boun.edu.tr/starteng.html),7 our in-house whole-
genome/exome database from more than 3,000 neurologically normal
individuals (including 10 of Turkish descent), and has only one allele in
the ExAC database (South Asian: 1/7,878, allele frequency 5
0.0001269; http://exac.broadinstitute.org/). It had been predicted to
be pathogenic using the SIFT,8 CADD,9 and PolyPhen210 algorithms
and a rare disease causal by a logistic regression model described
elsewhere.11 Because of this, and because of recent functional data
showing that cultured fibroblasts of a patient with this mutation have
lipid peroxidation, mitochondrial dysfunction, and subsequent mito-
chondrial membrane abnormalities,12 we believe that this mutation is
the cause of disease in this family.
This is the same mutation that Paisan-Ruiz et al.3 described in a
consanguineous index case from Pakistan, which presented with
different clinical features. In order to explain this phenotype
variability, we hypothesized that variation in genes associated with
different PLAN phenotypes, as well as PD and other neurodegenera-
tive disorders (Supplementary Box S1), may be acting as genetic
modifiers. To test this possibility, variation in these genes was further
investigated in the WGS data generated. Results derived from this
analysis are summarized in Supplementary Table S1. A novel
heterozygous c.3883TRC transition in exon 28 of LRRK2 that is
present in the index case and her unaffected brother deserves special
mention. This variant is not present in public databases or our in-
house database. It results in a p.W1295R substitution in a highly
conserved region (Supplementary Figure S2) within the Leucine-Rich
Repeat domain of the LRRK2 protein, which is known to participate in
Video 1. Index case video clip. The first part of the video shows the patient before starting any treatment. She had generalized severe bradykinesia, hypomimia,
and intermittent arm tremor, and was not able to stand up or walk on her own. The second part of the video shows the patient after the establishment of a
subcutaneous apomorphine pump (5mg/hour). Although she was able to get up and walk again, mild bradykinesia and hypomimia, and mild postural instability are
still noted.
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interactions with other proteins through binding to its extended
solvent-accessible surface.13 The identified substitution alters the three-
dimensional conformation of this domain as predicted by in silico
analysis (Supplementary Figure S2) and affects its charge and
hydrophobicity, which may affect interaction with other proteins.
Another variant of interest was identified in DCTN1, which is
associated with Perry syndrome, an autosomal dominant neurodegen-
erative disorder characterized by late-onset parkinsonism.14 The
identified variant is a heterozygous c.35GRA transition in exon 2 of
the gene, resulting in a p.T12M substitution that is present in ExAC
with a frequency of 0.00003398 (European: 2/64,482, allele frequency
5 3.102E-5; Latino: 2/11,478, allele frequency5 0.0001742). It is in a
well-conserved region among human, macaque, mouse, and rat, and
slightly alters its three-dimensional conformation (Supplementary
Figure S3).
Discussion
In this report, we describe a 33-year-old index case with parental
consanguinity (Figure 1A) who presented with early-onset Parkinsonism.
WGS of this individual and an unaffected brother revealed that a
homozygous p.R747W mutation in PLA2G6 segregates with the disease in
this family. A recent publication by Kinghorn et al.12 shows that knockout
of the PLA2G6 homologue in Drosophila results in reduced survival,
locomotor deficits, and organismal hypersensitivity to oxidative stress, as
well as mitochondrial respiratory chain dysfunction, reduced ATP synthesis,
abnormal mitochondrial morphology, and increased lipid peroxidation
levels. Replication of these findings in cultured fibroblasts of a patient with
p.R747W mutation strongly supports that the mutation described herein is
the cause of disease in this family.
Paisa´n-Ruiz et al.3 identified the same mutation in a consanguineous
index case from Pakistan. This individual, however, had an earlier age at
onset (18 vs. 27 years) and different clinical symptoms, including rapid
cognitive decline with personality changes, foot dystonia, blepharoclonus,
and asymmetric pyramidal features with spasticity.3,15 The clinical
differences between these two patients suggest an absence of a genotype–
phenotype correlation for this mutation, unlike the one proposed for
p.D331Y mutation carriers.5 In order to explain this phenotype variability,
we contemplated the possibility that variation in genes associated with
different forms of neurodegeneration (including PLAN and PD) may be
acting as genetic modifiers. Further examination of the WGS data
generated revealed the presence of two heterozygous missense variants in
LRRK2 and DCTN1 in both the index case and her unaffected brother. The
role of these variants as genetic modifiers of p.R747W deserves further
investigation in a larger dataset.
The phenotypes associated with mutations in this gene are
heterogeneous, ranging from INAD to autosomal recessive
Parkinsonism. The index case presented herein was diagnosed with
levodopa-responsive PD and did not present any signs of brain iron
accumulation, which is in line with a recent literature review by
Karkheiran et al.15 in which only eight patients (33%) presented iron
depositions. A summary of the clinical features and cerebral imaging
results in all individuals with levodopa-responsive PD and no signs of
brain iron accumulation reported to date is shown in Supplementary
Figure S3. This shows that both the associated clinical symptoms and
the imaging findings (other than brain accumulation) vary considerably
among these individuals, suggesting that no specific clinical or cerebral
imaging pattern can be associated with PLA2G6 mutations.
In summary, we present a consanguineous PD case from Turkey
with genetically confirmed PLAN. This result supports the importance
of prioritizing this gene in mutational analysis of autosomal recessive
PD cases, and confirms the clinical heterogeneity of PLAN. We also
found two heterozygous variants in LRRK2 and DCTN1 in both the
index case and her unaffected brother. The role of these variants in
families with this mutation deserves further investigation.
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